Investigators are now planning a larger clinical trial to test the bacteriotherapy's safety and efficacy.

Monday, February 22, 2021 NIAID Trial Finds Topical Bacteriotherapy Safely Reduces Amount of S. aureus on People with Eczema A NIAID-funded clinical trial has found that one week of topical treatment with a bacterium isolated from healthy human skin, Staphylococcus hominis A9, safely decreased the amount of Staphylococcus aureus inflaming the skin of people with moderate to severe eczema. Also known as atopic dermatitis, eczema is a chronic inflammatory skin disease characterized by dry, itchy skin and rashes. S. aureus colonizes the skin of people with eczema and exacerbates the disease by promoting inflammation. Investigators are now planning a larger clinical trial to test the safety and efficacy of Staphylococcus hominis A9 for treating eczema. A mid-sized clinical trial of another bacteriotherapy developed by NIAID scientists for treating the disease is underway. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107